Amarin Corp Plc (AMRN)

[Notademoc]

Sanofi and Regeneron in February cut the list price of Praluent by 60 percent to match the price of Amgen Inc's Repatha, another treatment to cut the risk of heart attacks, as the drugmakers try to boost the sales of the drug.

The new list price for Praluent will be $5,850 a year, down from more than $14,000 a year, when it was first approved in 2015.

Sales of both Praluent and Repatha have been severely constrained by roadblocks put up by insurers looking to limit spending on the expensive drugs.